Hemostasis System in Patients with Schizophrenia and Schizophrenia Spectrum Disorders.
endogenous mental disorders
hemostasis
neuroinflammation
pathogenesis
“Fibrinodynamics”
Journal
Bulletin of experimental biology and medicine
ISSN: 1573-8221
Titre abrégé: Bull Exp Biol Med
Pays: United States
ID NLM: 0372557
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
received:
11
05
2023
medline:
12
2
2024
pubmed:
12
2
2024
entrez:
12
2
2024
Statut:
aheadofprint
Résumé
Hemostasis system in patients with schizophrenia and schizophrenia spectrum disorders was examined using "Fibrinodynamics" technology that allows evaluating the overal coagulation, fibrinolysis, and hemostasis potentials. All indices, except for the parameter characterizing the hemostasis balance, were statistically higher (p<0.0001) in patients than in healthy volunteers (control). In most patients, the hemostasis system remained balanced despite changes in individual coagulation and fibrinolysis parameters. The obtained results have a fundamental importance, expand the understanding of the pathogenesis of endogenous mental disorders, and are useful for the development of personalized approaches to the treatment of these patients.
Identifiants
pubmed: 38345675
doi: 10.1007/s10517-024-06030-1
pii: 10.1007/s10517-024-06030-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Rupprecht R, Rupprecht C, Di Benedetto B, Rammes G. Neuroinflammation and psychiatric disorders: Relevance of C1q, translocator protein (18 kDa) (TSPO), and neurosteroids. World J. Biol. Psychiatry. 2022;23(4):257-263. https://doi.org/10.1080/15622975.2021.1961503
doi: 10.1080/15622975.2021.1961503
pubmed: 34320915
Buckley PF. Neuroinflammation and schizophrenia. Curr. Psychiatry Rep. 2019;21(8):72. https://doi.org/10.1007/s11920-019-1050-z
doi: 10.1007/s11920-019-1050-z
pubmed: 31267432
Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, Brizard B, El Hage W, Surget A, Belzung C, Camus V. Neuroinflammation and depression: A review. Eur. J. Neurosci. 2021;53(1):151-171. https://doi.org/10.1111/ejn.14720
doi: 10.1111/ejn.14720
pubmed: 32150310
Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 2018;44(5):973-982. https://doi.org/10.1093/schbul/sby024
doi: 10.1093/schbul/sby024
pubmed: 29648618
pmcid: 6101562
Khamisy-Farah R, Fund E, Raibman-Spector S, Adawi M. Inflammatory markers in the diagnosis of fibromyalgia. Isr. Med. Assoc. J. 2021;23(12):801-804.
pubmed: 34954920
Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90(12):1338-1346. https://doi.org/10.1136/jnnp-2018-319586
doi: 10.1136/jnnp-2018-319586
pubmed: 31175169
Medications that Affect Hemostasis, in Diagrams and Tables. Voronezh, 2019.
Saraeva NO. Hematology. Irkutsk, 2015. Russian.
Lalic-Cosic S, Dopsaj V, Kovac M, Pruner I, Littmann K, Mandic-Markovic V, Mikovic Z, Antovic A. Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia. Int. J. Lab. Hematol. 2020;42(3):322-330. https://doi.org/10.1111/ijlh.13183
doi: 10.1111/ijlh.13183
pubmed: 32190981
Brusov OS, Matveev IA, Kirillov PS, Faktor MI, Karpova NS, Vasilyeva EF, Katasonov AB, Zozulya SA, Klushnik TP. Risk assessment of thrombotic events in patients with schizophrenia and schizoaffective disorder in the acute state: the “Fibrinodynamics” technology. Zh. Nevrol. Psikhiatr. 2017;117(11):91-100. Russian. https://doi.org/10.17116/jnevro201711711191-100